Foreign-invested pharmaceutical firms remain concerned about successive cost cutting measures

In parallel with a series of the government measures aimed at reducing pharmaceutical spending for better finance stability in the National Health Insurance Corp., including a drug price re-evaluation system, a minimum drug price system, and restricted reimbursement, foreign-invested pharmaceutical firms seems likely to experience a serous setback in sales.

The foreign pharmaceutical firms ...